Navigation Links
Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
Date:4/4/2008

tively advance its drug candidates.

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "This has been a challenging process, but through these measures we believe that we have designed a strategy by which we will conserve our financial resources and strengthen our ability to execute on our goals to move our drug candidates forward, thereby better positioning the Company for future success." Mr. Weiss continued, "I would like to especially thank Dr. Craig Henderson for his long and dedicated service to the Company."

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release anticipating future clinical and business prospects for our drug candidates may be
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
2. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
3. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
5. Keryx Biopharmaceuticals Announces Additions to Management Team
6. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
9. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
10. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... molecules in a living cell is something that has long ... diamond, may well be able to do this and potentially ... for, hard-to-cure diseases such as cancer. In a ... Physics and the German Physical Society,s New Journal of ...
... & Co. Inc., a unit of Oppenheimer Holdings, is pleased ... as Managing Director in the Healthcare group of the Firm,s ... science business. He will report to Brian McCarthy, Managing Director ... 2003, Matthias had worked at JMP Securities, where he was ...
... FREMONT, Calif., May 18, 2011 Biomerix Corporation and ... Biomerix 3D Scaffold , a novel three-dimensional tissue ... the Biomerix 3D Scaffold to research institutions across Europe. ... polycarbonate polyurethane , the Biomerix 3D Scaffold is ...
Cached Biology Technology:'Critical baby step' taken for spying life on a molecular scale 2Biomerix Corporation Reaches European Distribution Agreement with Cellon S.A. 2
(Date:4/22/2014)... lead a five-year, $3 million study to determine whether ... transport of dissolved organic matter (DOM) through the Connecticut ... chemical composition and water quality of the watershed and ... Science Foundation,s MacroSystems Biology program, researchers will collect data ... in Canada and runs through five U.S. states, before ...
(Date:4/22/2014)... JUPITER, FL, April 22, 2014 Scientists from the ... identified a protein complex that plays a critical but ... , The study, which showed a novel role for ... 2014 in the journal eLife , a publisher ... Planck Society and the Wellcome Trust. , "This is ...
(Date:4/22/2014)... Inspired by the fist-like club of a mantis ... California, Riverside, in collaboration with University of Southern California ... composite materials that is more impact resistant and tougher ... we study the club of this tiny crustacean, the ... things we use every day," said David Kisailus, a ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3Scientists identify critical new protein complex involved in learning and memory 2Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3
... MA Obesity is associated with a worse prostate ... genetic mutation, suggest results from a new study led ... Institute and Brigham and Women,s Hospital researchers. Among prostate ... a more than 50% increased risk of dying from ...
... trash could spell big trouble for marine life, starting with ... and the University of Exeter who report their evidence in ... Current Biology on December 2. Those marine worms play ... for other animals. Work by Stephanie Wright from the ...
... Vicente was recently awarded a grant of more than $2 ... continue Phase III of the Initiative for Maximizing Student Development, ... of Chemistry and Professor of Chemotherapy/Materials in the Department of ... the IMSD Program is giving us the opportunity to continue ...
Cached Biology News:Genetic mutation may play key role in risk of lethal prostate cancer in overweight patients 2Microplastics make marine worms sick 2LSU receives $2 million from NIH for biomedical sciences training for underrepresented students 2
delta-like 1 homolog (Drosophila)...
...
... BMH 71-18 mutS and ES1301 mutS ... coli. Use of these strains prevents repair ... leading to high mutation efficiencies and making ... GeneEditor and Altered Sites II Mutagenesis Systems. ...
Polaroid black & white positive, 3 x 4 inch pack film, ISO 3000/ 36 ASA DIN (20 expsures). For use in the Polaroid Direct Copy Camera (PHC34)....
Biology Products: